A conservative doctor is taking on the battle against the so-called “acne pill,” claiming the medicine has been shown to be effective in treating the condition.
The drug, called a glycolic acid, has been touted as a potential treatment for skin cancer and has even been used to treat a rare form of epilepsy.
The pill is often sold by online drug stores, but Dr. Brian Bouchard, a dermatologist at the University of Toronto, is taking a different approach.
He’s arguing that the drug works by targeting an enzyme that converts a protein called erythroidin to a harmless chemical called cytochrome c, a process that causes skin cells to become damaged.
Bouchards team has been studying the drug, using a drug called S. pylori eliminator, since March.
“This study is a great example of a pharmaceutical company using science to create a product that actually works,” Bouchars said.
“There are a number of companies using this drug in the US.
So what we’re trying to do is show that the way to treat acne is not just to get rid of it.
It’s to make it look better and to keep it under control.”
Bouchar says the drugs are a step in the right direction for people who suffer from acne, but he says the drug is not a cure.
“I don’t think that there’s a silver bullet for acne,” he said.
“Acne is really just one of those conditions that is very, very hard to treat.”
The drug is a treatment for cytochromes, or proteins that help cells keep healthy.
Acne has been linked to an increased risk of skin cancer, diabetes and cardiovascular disease.
Bouchard is concerned that the anti-acne drug may have adverse side effects.
Dr. Brian A. Boudreau, who specializes in the management of acne, says the study is important.
“[There’s] a very small number of people who have this condition, so this is a very important study that shows that it’s possible to reduce the incidence of this condition in those individuals,” he told CBC News.
He said that while the study shows that the skin may not get worse, the drugs may actually increase inflammation, causing the skin to turn red.
A lot of people with acne are not aware of this, he said, and if they are, they may try to use topical treatments.
The drug is currently being tested in a clinical trial in Toronto.
Sylvain Bouchault, a Montreal-based dermatologist who is a member of Boucha’s team, said he has received complaints from patients who were using the drug to treat their skin condition.
But Bouchas group has already started to test its effectiveness in people who are in remission.
We have been trying to develop a treatment that has been approved by the FDA for this condition and that is being used in trials.
In Quebec, Dr. Marie-Claire Dejemeire has taken on a new form of treatment for the condition that involves using a topical formulation to treat the affected area.
This new treatment has been successfully used to reduce inflammation, and this will be a major step forward in terms of finding a better treatment,” she told CBC Radio’s As It Happens.
Dejemeires group also has started a new trial, which has tested the drug on skin cells that normally don’t grow on the face.
She says it’s been working well, and the company hopes to get the drug approved in the next few months.
Although the treatment has proven to be a success, some people are still skeptical.
I’m not convinced it’s going to work, I think that the placebo effect is going to take over,” said Joanne D’Aubuisson, a mother of two who was diagnosed with acne at the age of six.
When asked about the new drug, Bouch’s team was adamant that it would work.
“We’re convinced that this is going be effective,” said Bouch.
It’s important for people to understand that it is a medication, so the side effects are minimal,” he added.
Despite the fact that there have been a number different versions of the acne pill, there has been a clear consensus among dermatologists that there is one that works, he added, because it’s a compound that is a combination of cytocholic acid and another molecule called pyrrolidin.
According to a recent study published in the journal Science Translational Medicine, the compound is effective at blocking cytochanin-1, an enzyme involved in cell death.
Researchers at Johns Hopkins University recently published a study that found the drug can reduce the risk of developing skin cancer in mice, though the study has yet to be published.
Some people who want to get treatment from a doctor have taken